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Uncommon Cardiomyopathies
Efstathia I. Prappa, MD, Fotios Tsakalis, MD,  
Charalampos Kavouras, MD, Nikolaos Lavos, MD,  
George Bakosis, MD, Antonios Sideris, MD
A b s t r A c t
Anderson-Fabry Disease (AFD) is an X-linked recessive lysosomal disorder, lead-
ing to multisystemic disease because of abnormal glycosphyngolipids widespread 
accumulation, the result of α-galactosidaseA deficient activity. Cardiac involvement 
is common; includes left ventricular hypertrophy and gradually impairing cardiac 
function. Although the disease is unveiled in childhood and culminates in cardiac, 
cerebrovascular and end-stage renal disease, diagnosis is often delayed or missed. 
Recently established enzyme replacement therapy (ERT) may improve most of the 
disease’s manifestations. Early diagnosis is thus crucial for AFD patient management.
Isolated non-compaction of the ventricular myocardium (IVNC) is a rare congenital 
form of cardiomyopathy. It is characterized by the postnatal persistence of the em-
bryonic pattern of myoarchitecture, consistent of prominent trabeculations and deep 
intertrabecular recesses, and assumed to occur as a consequence of intrauterine ar-
rest of myocardial compaction. Contemporary diagnosis has been facilitated by the 
introduction of specific morphologic criteria by echocardiography and magnetic reso-
nance imaging. Management issues revolve around the management of heart failure, 
arrhythmias and thromboembolic events in order to prevent the significant morbidity 
and even mortality that has been associated with this entity. Significant overlapping 
with many other forms of cardiomyopathies suggest that non-compaction may be a 
morphologic trait rather than a distinct cardiomyopathy.
I N t r O D U c t I O N
Inherited cardiomyopathies are infrequent myocardial disorders, compared to 
ischemic, valvular or hypertensive heart disease. Among them, there are really rare 
diseases, which “deserve” to be referred to under the term “rare or uncommon cardio-
myopathies”. Two of these cardiomyopathies will be described in this review.
F A b r Y  c A r D I O M Y O P A t H Y
Anderson-Fabry disease (AFD, synonym Fabry disease) is an X-linked lysosomal 
storage disease (LSD) caused by mutation in the gene encoding the lysosomal enzyme 
α-galactosidase A (α-Gal A). The resultant deficiency in α-Gal A activity leads to 
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intra-lysosomal accumulation (“vacuolization”) of neutral 
glycosphingolipids, mainly globotriasylceramide (Gb3), in 
various organ systems.
AFD is a rare, panethnic disorder; incidence has been 
estimated at 1 in 40.000 to 1 in 117.000 live births for males.1 
However, over the last decade, scientific evidence based on 
patient cohorts with unexplained left ventricular hypertrophy 
(LVH), thought to be due to sarcomeric hypertrophic cardio-
myopathy (HCM), identified 7% of males2 and 12% of females3 
with either biochemical or genetic evidence for Fabry disease. 
The heightened cardiological interest was to be expected as 
the probable AFD population expanded.
c L I N I c A L  P r e s e N t A t I O N
As mentioned above, the pathophysiological mechanism 
of AFD is the Gb-3 abnormal accumulation (“vacuolization”) 
in lysosomes of vascular endothelium and smooth muscle cells 
of blood vessels, in gaglion cells, in many cell types in the 
heart, kidneys, eyes and most other tissues. That leads to a 
complex and multisystemic disorder, with symptoms starting 
early in life.1
During childhood, the clinical onset typically occurs with 
acute, mostly burning pain in the extremities (“acroparesthe-
siae”) or in any region of the body, due to stored sphingolipids 
in the dermal axons. Some complain about neck pain and 
headache (not always distinguishable from migraine or cluster 
headaches). Physical activity, high temperature, foods (cof-
fee, meat), alcohol, emotional stress can trigger the pain, not 
responding to common painkillers. Chronic pain has been 
described as the most debilitating symptom in patients with 
AFD. Additional symptoms include heat/cold intolerance, 
recurrent fever, and hypohidrosis (due to impaired sympathetic 
innervation of the skin and sweat glands dysfunction from 
deposition of storage material). Corneal opacities (corneal 
verticillata) have been described as almost pathognomonic for 
AFD (occur in 75% in female and up to 90% in male patients) 
and do not affect the vision (“Fabry cataract”). The diagnosis 
is only made by split-lamp examination.
During adolescence, the classic angiokeratoma appears. It 
is a pinhead sized, reddish-purple maculopapular skin lesion 
(‘rush’), not disappearing with pressure. Typical locations 
are the fingertips, the bathing trunk area, the buttocks, the 
periumbilical area, but may also occur on the mucosa (on 
the lips or anywhere in the gastrointestinal tract) (Fig. 1). In 
adulthood, renal dysfunction, cerebrovascular complications 
and cardiac disease are already apparent.
Although proteinouria (regarded as the earliest sign of 
clinically relevant renal involvement in AFD) is presented 
from the second decade of life, by age 47, half of all untreated 
patients have already developed terminal renal failure. Renal 
biopsies in children have shown that lipid storage in podocytes 
and glomerular, interstitial or vascular changes develop even 
before clinical renal functional impairment occurs. Relative to 
central nervous system, the most severe complication in AFD 
are transient ischemic attacks (TIA) and stroke. Almost 25% of 
patients experience a cerebrovascular event over the course of 
their disease (mean age 34 years in men, 54 years in women).
FIgUre 1. Angiokeratoma a) on the hands; b) periumbilically; 
c) on the lips [Beck M: “Fabry disease, 2nd ed. 2007”].
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c A r D I A c  I N v O Lv e M e N t
Cardiac involvement is common but variable and clinical 
severity increases with increasing age. On average, more than 
50% of patients with AFD have cardiac symptoms at the age 
of 36. Myocardial Gb3 deposits (in myocytes, conduction 
system, vascular endothelium, valve tissue) represent 1-2% of 
the total cardiac mass.4 Therefore, it is likely that disease in 
the heart results from activation of other signaling pathways 
(inflammation, neuron-hormonal dysregulation) that lead to 
hypertrophy, apoptosis, necrosis and fibrosis. Myocardial is-
chemia in the absence of significant disease of epicardial arter-
ies and substantial fibrosis are major determinants of cardiac 
remodeling in AFD and contribute to disease progression.
a. cardiomyopathy. Most patients (male and female) with 
AFD develop LVH. Early disease is characterized by concen-
tric remodeling, progressing later to concentric hypertrophy. 
Asymmetric septal hypertrophy, indistinguishable from that 
seen in sarcomeric cardiomyopathies (dynamic LV outflow 
obstruction may be seen) accounts for only 5% of cases2,4,5 
The right ventricle may also be affected. LV systolic function 
seems to be preserved, when conventional methods are used 
for estimation.4 Nonetheless, studies using tissue Doppler 
imaging (TDI) and strain-rate imaging (SRI) have demon-
strated reductions in systolic performance, occurring earlier 
in the longitudinal than in the radial dimension.6 It seems that 
early functional abnormalities can be detected using advanced 
echocardiographic techniques prior to the development of 
morphological changes (LVH or fibrosis).6a Early diagnosis 
might enable the optimal therapy initiation.6b Mild diastolic 
dysfunction is a common feature of AFD, although restrictive 
pathophysiology may be identified in the most advanced stages 
of the disease associated with pronounced fibrosis.4
Some authors focused on the recognition of AFD from 
other forms of LVH by non-invasive imaging hallmarks. Thus, 
Pieroni et al compared echocardiographic features of patients 
with AFD, sarcomeric HCM, LVH secondary to hypertension 
and normal control subjects.7 He identified thus a specific 
echocardiographic feature of AFD, reflecting the peculiar 
pathological substrate of the disease observed at histology and 
ultrastructural analysis of endomyocardial biopsy tissue. Ultra-
sound examination in AFD patients revealed a binary appear-
ance of LV endocardial border, systematically absent in HCM 
and hypertensive patients as well as in normal control patients, 
thereby resulting in a distinguished echocardiographic feature 
with a sensitivity and specificity of 94% and 100% respectively, 
suggesting that binary appearance is an ideal discriminator of 
AFD from hypertophic cardiomyopathy (HCM), thus an ideal 
non-invasive diagnostic hallmark of Fabry cardiomyopathy 
(Fig. 2). Taking it further, other authors with the same study 
design,8 anticipated that the binary appearance is likely to be 
affected by image quality, gain settings and imaging software, 
making the conclusion that this specific echo-sign is poorly 
reproducible and lacks sensitivity and specificity (35% and 
79% respectively in their own study) to be used as an echo-
FIgUre 2. Two-dimensional echocardiography in 4-chamber apical view and LV endomyocardial biopsy from two patients with 
AFD (A, D and B, E) and a patient with sarcomeric HCM (C, F). Comparison of the three echocardiographic frames reveals the 
presence of a binary appearance of LV endocardial border in the two AFD patients (A, B). This echocardiographic finding reflects 
the glycosphingolipids compartmentalization involving a thickened endocardium (End) with enlarged and engulfed smooth muscle 
cells (SMC), a subendocardial empty space (SES), and a prominent involvement of subendocardial myocardial layer (SL), while the 
middle layer (ML) appears partially spare (D, E). The echocardiographic pattern is absent in HCM (C), despite a similar thickening 
of the endocardium (F) [Pieroni et al, JACC 2006;47:1663-1671] (permission granted). AFD = Anderson-Fabry disease; HCM = 
hypertophic cardiomyopathy; LV = left ventric-cle(-ular).
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cardiographic screening tool for AFD.
In that direction, cardiac MRI could be used as discrimina-
tor of AFD from HCM. In MRI studies, patients with Fabry’s 
related LVH showed LV delayed-enhancement with a typical 
and consistently founded pattern, characterized by the involve-
ment of the inferolateral basal or mid basal segments and a 
mesocardial distribution spared the subendocardium.9 The 
pattern seems to be specific to AFD; in fact, patients with 
symmetric sarcomeric HCM had variable locations and dis-
tributions of delayed enhancement, mainly in interventricular 
septum and papillary muscles.10
b. valvular disease in AFD is caused by infiltrating 
changes within valvular fibroblasts. Left heart valves are most 
frequently affected, although pulmonary valve involvement is 
also reported. Typically, valves are thickened and distorted, 
resulting in mild-to-moderate regurgitation; severe disease re-
quiring surgical operation is infrequent. Aortic root dilatation 
resulting to aortic valve insufficiency is may be seen.
c. Myocardial ischemia: Although the incidence of myo-
cardial infarction is low in AFD patients, angina pectoris and 
chest pain are frequent, particularly in patients with LVH. 
Studies using positron emission tomography (PET) have shown 
that patients with AFD and angiographically normal epicardial 
coronary arteries have reduced coronary flow reserve, sug-
gesting that microvascular dysfunction may be responsible for 
exertional symptoms.11
d. electrophysiological abnormalities: Resting ECG is 
almost always abnormal (Fig. 3) Voltage criteria for LVH and 
repolarization changes are the most common abnormalities. 
Many patients have a short PR interval probably caused by 
accelerated AV conduction due to nodal Gb3 infiltration. With 
disease progression, patients develop bundle branch block, 
AV conduction delay and progressive sinus node dysfunc-
tion, requiring pacemaker implantation.12 Supraventricular 
tachycardias, atrial fibrillation and flutter are frequently 
observed,12 although individual cases of fatal malignant ar-
rhythmias requiring implantable cardioverter defibrillator 
(ICD) implantation are also reported.
D I s e A s e  P H e N O t Y P e s - D I A g N O s I s
The disease is classified into two major phenotypes ac-
cording to the onset of clinical symptoms and the absence or 
presence of residual α-Gal A activity.
the early onset (or classic type) characterized by early 
manifestation of the multi-systemic disorder, while cardiac 
involvement is appears later in life. Males with classic disease 
FIgUre 3. ECG showing left ventricular hypertrophy (LVH), repolarization abnormalities and short PR interval in AFD. AFD = 
Anderson-Fabry disease
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have no or very low α-Gal A activity and the diagnosis is easily 
made by determining that in plasma or peripheral leukocytes. 
Tissue biopsy may also establish the diagnosis, revealing the 
typical “vacuoles” by electron microscopy.
the late onset (atypical form or cardiac/renal variant) 
patients are usually asymptomatic until their late thirties, and 
their clinical manifestations are then limited to the heart/
kidneys. These male patients have some residual plasma enzy-
matic activity and biochemical diagnosis is possible, but tissue 
biopsy is pathognomonic when targeting into heart/kidney and 
not throughout the body.2,13
Although AFD has been considered an X-linked recessive 
disorder, affected women are increasingly recognized3 (with 
clinical status ranging from asymptomatic to full-blown disease 
as severe as that in affected males), suggesting that the disease 
follows an X-linked-dominant rather than –recessive trans-
mission. The variability in females may be partly accounted 
for by a nonrandom or skewed inactivation of the wild type 
X-chromosome, but other factors such as genetic modifiers 
may play a role. Women carriers can have normal to very low 
α-Gal A activity; therefore their specific family mutation in 
the α-Gal A gene must be demonstrated for the diagnosis to 
be made. Tissue biopsy is diagnostic, when targeting to the 
affected organ.
Prenatal diagnosis can be made by demonstration of an Xy 
karyotype and deficient α-Gal A activity in cultured amniocytes 
or chorionic villi.14 If the family’s mutation is known, molecular 
studies can replace or confirm the enzymatic diagnosis.
In conclusion, the clinical course of AFD is heterogeneous 
and variable. The range of possible differential diagnoses is 
broad and concerns many medical (overlapping) subspecialties. 
The risk of a delayed or incorrect diagnosis is probably high. 
The time period of symptoms onset to the correct diagnosis 
is long:1 13 years in men and 17 years in women!
P r O g N O s I s
Progressive renal failure, cardiomyopathy and myocardial 
infarction, as well as TIAs and strokes reduce the survival 
time for male untreated patients with AFD to an average 
of 55 years, for women to 70 years.15,16 The quality of life is 
obviously reduced compared with the normal population.1 A 
multisystemic disease that is accompanied by chronic pain, that 
has a far too long diagnostic latency period and a substantially 
lower life expectancy is necessarily also accompanied by an 
increased risk of depression.
t H e r A P Y
Until 2001, treatment for AFD patients was only sympto-
matic. Patients with chest pain should receive conventional 
anti-aginal treatment, like β-blockers (with the provision 
that medicines may aggravate the tendency of some patients 
to symptomatic bradycardia and AV conduction block) or 
dihydropyridine calcium channel blockers (relatively effec-
tive and safe), while antiplatelet treatment should be offered 
to all symptomatic patients. Angiotensin converting enzyme 
(ACE) inhibitors and diuretics should be used in patients 
with evidence for systolic impairment, while patients with 
advanced congestive heart failure may be candidates for heart 
transplantation (the intrinsic enzyme production within the 
graft should prevent reoccurrence of disease). Pacemaker 
implantation may be required for conduction abnormalities 
or ICD implantation for malignant arrhythmias. ACE inhibi-
tors should be considered in any patient with proteinouria or 
renal insufficiency.
Since 2001, enzyme replacement therapy (ERT) is avail-
able. Two preparations have been licensed for the causal 
treatment of AFD in Europe, both are gene technologically 
produced α-Gal A variants based on human DNA, adminis-
tered periodically as infusions. The treatment is entirely safe 
(allergic reactions, headache, flushing, raised temperature, 
chills, nausea and vomiting may occur) and has to be continued 
for lifelong. The cost amounts to 250 000 euros per patient 
per year!
Several studies have shown that ERT is effective in quality 
of life reducing symptoms (pain,17 angina pectoris,18 gastro-
intestinal19 and sweating disturbances), in cardiac involve-
ment (regression or no progression of LVH,20 improvement 
of systolic performance indices6), as well as in renal failure 
(dissolving Gb3 storage in glomeruli leading to improvement 
in creatinine clearance17,18). Obviously, it has been possible 
for only very few studies to be conducted in a double blind, 
randomized and controlled fashion, as patients with a known 
diagnosis of AFD were given causal therapy after the prepara-
tions had become licensed. The available information about 
the long term treatment with ERT comes mostly from cohort 
studies that were developed from the two available patient 
registries, or from open extension studies of the phase III 
trials. Nonetheless, it is clear that patients with AFD benefit 
from ERT. It seems that ERT initiation in the early phases 
of the disease would be more effective than waiting until 
measurable organ damage develops. However, even 9 years 
after ERT has been introduced, many therapeutic questions 
remain unresolved- for example, whether the treatment is able 
to prevent relevant organ manifestations and reduce mortality 
due to AFD.
c O N c L U s I O N
AFD is an important differential diagnosis in middle 
aged and elderly patients with unexplained LVH. Emerging 
evidence suggests that ERT substantially improves many of 
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the features of that malignant disease, including some aspects 
of cardiac involvement. Thus, correct and early diagnosis dra-
matically improves the prognosis of AFD patients.
I s O L A t e D  v e N t r I c U L A r  
N O N - c O M P A c t I O N
Noncompacted myocardium is a rare myocardial disor-
der, with prevalence estimated 0.014% of patients referred 
for echocardiography.1 The phenotype resembles “persistent 
intramyocardial sinusoids”, a well-known cardiac anomaly 
among pediatric cardiologists. However, the latter are asso-
ciated with congenital obstructive lesions of the right or left 
ventricular outflow tract, such as pulmonary22 or aortic23 atresia 
with intact ventricular septum. In these patients, regression 
of the embryogenic sinusoids is impaired during ontogenesis 
by ventricular pressure overload that results in deep recesses 
that communicate with both the ventricular cavity and the 
coronary artery system.
By contrast, isolated ventricular noncompaction (IVNC) 
is defined as idiopathic cardiomyopathy characterized by an 
altered structure of the myocardial wall (consistent by promi-
nent trabeculations and deep intratrabecular recesses), as a 
result of intrauterine arrest of compaction of the myocardial 
fibers, in the absence of any coexisting congenital lesion.24,25
Since the first reported case of IVNC in 198626 and a 
more extensive description in 1990,24 case reports27-29 and a 
few studies in paediatric30,31 and adult populations25,32-35 have 
been published. However, IVNC remains an unclassified 
cardiomyopathy according to WHO classifications of cardio-
myopathies.36,37
P A t H O g e N e s I s
In the early embryo, the heart is a loose interwoven mesh 
of muscle fibers.38 During the first six weeks of fetal life, before 
the development of the coronary circulation, the human LV 
endocardium consists of a spongy meshwork of abundant fine 
trabeculae with deep intertrabecular recesses, which serve 
to increase myocardial oxygenation. At 12 weeks, when ven-
tricular septation is complete, the trabeculae start to solidify 
at their basal area contributing to added thickness of the com-
pacted myocardial layer. The large spaces within the trabecular 
meshwork flatten or disappear. Compaction of the ventricle 
progress from the epicardium to the endocardium and from 
the base of the heart to its apex, is a process more complete in 
the left than the right ventricle and is finally completed in the 
early fetal period.39 Although the cause of IVNC is not fully 
elucidated, it is believed to represent an arrest in endomyo-
cardial morphogenesis24 to embryonic phase, with prominent 
trabeculations and deep intertrabecular recesses (Fig. 4).
FIgUre 4. The process of normal trabecular compaction. (A) at 
first six weeks of fetal life, (B) at 12 weeks and (C) completion of 
myocardial compaction. [Sedmera et al, Anat Rec 2000;258:319-
337].
D I A g N O s I s
The defining characteristic of IVNC is trabeculations. 
However, prominent trabeculations (identified as discrete 
muscle bundles, more than 2 mm in diameter, that stand over 
the background of the LV endocardium) are considered to be 
common variant of the normal human heart40 or secondary to 
various cardiac diseases, developed after pathologic changes in 
the ventricular wall structure and cavity geometry.41 Therefore, 
IVNC diagnostic criteria were necessary, in order to differ-
entiate from other cardiac over-trabeculation conditions and 
normal variants.
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161
Three methods of criteria have ever proposed, based 
mainly on echocardiography:
A .  c H I N  c r I t e r I A 2 4
These focus on trabeculae at the LV apex. IVNC is defined 
by a ratio of X/y≤0.5, where X: the distance from the epicar-
dial surface to the trough of the trabecular recess, and y: the 
distance from the epicardial surface to peak of trabeculation. 
Measures obtained on the parasternal short axis and apical 
views, at end-diastole (Fig. 5).
FIgUre 5. X/y ratio calculation. X: the distance from the epi-
cardial surface to the trough of the trabecular recess, y: the dis-
tance from the epicardial surface to peak of trabeculation. [Chin 
et al, Circulation 1990;82:507-513] (permission granted).
b .  J e N N I  c r I t e r I A 4 2
 1. Absence of co-existing cardiac structural abnormalities.
 2. A two-layer structure, with thin epicardial compacted layer 
(C) and a thick endocardial non-compacted layer (N), con-
sisted with numerous, excessively prominent trabeculations 
and deep intertrabecular recesses, where a ratio N/C>2 
identifies IVNC (Fig. 6).
 3. Affected segments (trabeculated) are typically located in 
apex and mid-ventricular inferior/lateral wall.
 4. Recesses supplied by intraventricular blood on color Dop-
pler.
Measures obtained on parasternal short axis, at end-
systole.
c .  s t O L L b e r g e r  c r I t e r I A 3 3
 1. More than 3 trabeculations protruding from the LV wall, 
apically to the papillary muscles, visible in a single imaging 
plane, confirmed by echocardiography, MRI or computed 
tomography.
 2. Intertrabecular spaces perfused from the ventricular cavity, 
visualized on color Doppler.
The Chin et al criteria were the first diagnostic template, 
however eventually abandoned due to practical implications. 
The Stollberger et al criteria never gained general acceptance. 
Nowadays, the Jenni et al criteria are the most widely used, 
and although some of them are occasionally found in other 
heart diseases, their combination appears highly specific for 
IVNC diagnosis (specificity ≥95%).41
Apart from the pattern, location and extension of the tra-
beculations, the affected segments are typically hypokinetic, 
but hypokinesia may extend to morphologically unaffected 
FIgUre 6. N/C ratio calculation. N: non-compacted, C: compacted LV wall segment. [Jenni et al, Heart 2001;86:666-671] (permis-
sion granted).
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segments, resulting in a decreased LV ejection fraction. Left 
atrium is usually dilated. The right ventricle (RV) may be af-
fected25 (up to 40%), although diagnostically challenging be-
cause normal RV structure is also trabeculated. Therefore, the 
diagnostic contribution of RV morphology is rather qualitative. 
Isolated RVNC has not reported so far. Diastolic dysfunction is 
common, usually reflecting impaired LV relaxation and in rare 
cases of severe disease demonstrates restrictive physiology.
Thus, echocardiography has been the diagnostic procedure 
of choice, but the diagnosis is often missed because of the 
limitations of poor quality or near field imaging. In such cases, 
echo contrast imaging is strongly recommended in suboptimal 
studies, as it improves the endocardial border definition, al-
lowing a better delineation of the trabeculae and deep recesses 
filled by microbubbles.43 On the other hand, overestimation 
of myocardial trabeculations by 2D echocardiography (off-
axis apical or short-axis planes) is often made, leading to 
over-diagnosis of the disease by common criteria. As recently 
published,43a 3D echocardiography allows for an accurate 
measurement of the extent of noncompacted myocardium, 
due to its high spatial resolution and accuracy in volumetric 
quantification. It is, thus, superior to 2D echocardiography for 
the identification of pts with IVNC.
The role of cardiac MRI in IVNC diagnosis is critical, when 
echocardiographic windows are limited or when echocardi-
ography cannot distinguish reliably between IVNC and other 
cardiac pathology such as apical hypertrophy, endomyocardial 
fibroelastosis, metastatic disease or apical thrombus. Following 
echocardiographic criteria, MRI criteria for IVNC diagnosis44 
demand a ratio N/C >2.3, where N=non-compacted and 
C=compacted segment, measured at end-diastole. Left heart 
catheterization is not considered a first line diagnostic modality 
for IVNC diagnosis but rather helps exclude coronary artery 
disease as the cause of LV dysfunction.
c L I N I c A L  P r e s e N t A t I O N
Three major clinical manifestations of IVNC have been de-
scribed: heart failure, arrhythmias and thromboembolic events. 
Findings vary among patients, ranging from asymptomatic 
individuals identified by IVNC family screening, to disabling 
congestive heart failure patients. In a series of 65 patients 
with IVNC,35 heart failure (including NyHA class III-IV) 
presented in 83% of patients, palpitations in 6%, syncope in 
4%, chest pain in 4% and sustained ventricular arrhythmia in 
2%. When diagnosis was non-symptom based, familial referral 
was the main reason in 59% of patients, ECG abnormalities in 
23%, referral for “tricky” echocardiographic imaging in 12%, 
cardiac murmur in 5%. ECG is usually abnormal in IVNC 
(mostly presenting non specific repolarization abnormali-
ties, and BBBs, but cases of ventricular pre-excitation have 
been reported45). Dysmorphic facial appearance has been 
also reported (represented by prominent forehead, bilateral 
strabismus, low-set ears, micrognathia), but only in pediatric 
populations.24,30,31 Arrhythmias are the main reason for con-
cern in IVNC patients. Both supraventricular and ventricular 
tachyarrhythmias have been reported.24,25,32 It is hypothesized 
that due to fibrosis of the trabeculations and subendocardial 
ischemia, patients with IVNC are more prone to ventricular 
arrhythmias. Sudden cardiac death is a significant risk in these 
patients, with an incidence of 13-18% in some series.21,32,33 
Systemic thromboembolic complications can be a serious 
source of morbidity: cerebrovascular accidents, TIAs, and 
mesenteric infarction have been described.24,32 It seems that 
the excessively trabeculated noncompacted myocardium sets 
the ideal ground for thrombus formation. Paroxysmal atrial 
fibrillation and systolic dysfunction are additional proposed 
mechanisms for thromboembolism in IVNC.
g e N e t I c s
The studies looking into the genetics of IVNC suggest 
significant heterogeneity in the genetic substrate for this 
disorder. According to one report, up to 50% of infantile24 
and up to 18% of adult cases32 of IVNC are familial, with the 
remainder being sporadic. Both X-linked as well as autosomal 
transmission has been observed. In the former, mutations 
of the TAZ (G4.5) gene located in the Xq28 region cause 
IVNC associated with other neuromuscular disorders46 and 
affect male offspring (X-linked recessive). The majority of 
cases causing familial clustering in adults are not X-linked 
but rather transmitted in an autosomal dominant manner.47 
Several genes or chromosomal loci have been identified. Of 
these, mutations to the 11p15locus48 (gene unidentified) and 
to the Cypher/ZASP49 lead to isolated non-compaction or 
DCM, whereas mutations in the CSX or the DTNA46 genes 
are usually cause other congenital heart diseases in addi-
tion to non-compaction. It is, thus, difficult to make specific 
recommendations for genetic screening in patients identified 
as having IVNC. The prognostic significance of identifying 
any of the aforementioned genetic mutations is not clear. A 
detailed family history (focusing on sudden cardiac death, 
cardiomyopathies, heart failure and arrhythmias) is mandatory 
in all patients. Further genetic testing would be of interest in 
those with a positive family history. Echocardiographic imaging 
of first-degree relatives is well justified.
t H e r A P Y
There is no specific therapy for IVNC. Treatment is fo-
cused on the 3 major clinical manifestations: heart failure, ar-
rhythmias and systemic embolic events. Patients with reduced 
systolic function should be treated with standard medication 
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(ACE-inhibitors, diuretics, carvedilol). The indications for 
biventricular pacing are similar to the criteria employed for 
dilated cardiomyopathy. Heart transplantation should be 
considered for patients with IVNC who have end-stage heart 
failure. Holter monitoring should be considered once a year 
to detect asymptomatic arrhythmias. The indication for ICD 
therapy should be similar to those in dilated cardiomyopathy.
Prevention of embolic complication is crucial. Although 
early studies recommended anticoagulation for all patients 
with IVNC as soon as the diagnosis has been made, independ-
ent of ventricular function, to prevent embolic events,32 recent 
studies suggested that non-compaction itself is not thrombo-
genic50,51 and anticoagulation may be administered according 
to current recommendations (significant systolic dysfunction, 
atrial fibrillation and prior embolic events).
P r O g N O s I s
Early reports of the disease generally attached a very poor 
prognosis, in highly symptomatic patients affected by heart 
failure, sustained ventricular tachycardias or thromboembolic 
complications.24,30,32 Subsequent studies progressively broad-
ened our picture of the affected population, extending it to 
patients with less and less severe disease.34-35a Generally, the 
prognosis is not favorable. Progressive systolic dysfunction, 
arrhythmias and even sudden death are the major causes for 
morbidity and mortality, especially in symptomatic patients. 
Asymptomatic patients may have better prognosis, a delayed 
progression with less complications. Poor prognostic markers 
include the development of atrial fibrillation, bundle branch 
block, LV end-diastolic dimension >60 mm and NyHA class 
III-IV.32
c U r r e N t  s t A t U s
The new millennium “enthousiasm” has suggested IVNC 
as the 5th cardiomyopathy,42,52 in following classifications. The 
initial optimism shrunk as several studies highlighted the 
overlapping phenotype of familial IVNC with that of famil-
ial DCM and suggested that IVNC could be classified as a 
sub-type or variant of idiopathic DCM rather than a distinct 
cardiomyopathy in itself.34 Further studies demonstrated that 
IVNC phenotype can overlap with many other forms of car-
diomyopathies (in addition to the DCM), like hypertrophic 
and restrictive cardiomyopathies, suggesting that IVNC is a 
morphologic trait rather than a distinct cardiomyopathy.53 In 
a recent study,54 designed to determine the proportion of pa-
tients fulfilling IVNC criteria in an adult population referred 
to a heart failure clinic, an unexpectedly high percentage 
identified as IVNC patients (78.7%, 63.8% and 53.8% of 
patients, according to Chin,24 Jenni42 and Stollberger33 criteria 
respectively). The interpretation of the finding is that either 
IVNC is a quite frequent cardiac disease, or current criteria 
are too sensitive!
c O N c L U s I O N
Although in the USA IVNC is already classified as a pri-
mary genetic cardiomyopathy by the AHA,36 in Europe it still 
remains an unclassified one.37 It seems that there are still many 
controversies concerning diagnostic templates, nomenclature, 
prognosis and the necessity to classify IVNC as a distinct entity, 
rather demand a new nosographic definition.55,56
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